Market Overview
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 5.39 Billion |
| Market Size (2030) | USD 7.12 Billion |
| Growth Rate (2025 - 2030) | 5.71% CAGR |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
U.S. Contraceptive Devices Market Analysis by Mordor Intelligence
The United States contraceptive devices market is valued at USD 5.39 billion in 2025 and is on track to hit USD 7.12 billion by 2030, supported by a 5.71% CAGR during the forecast period. Growth holds steady despite post-Dobbs regulatory turbulence as consumers place higher priority on reproductive autonomy, Medicaid reimbursement expands, and employer-sponsored benefits add momentum. Long-acting reversible contraceptives (LARCs) gain popularity because of superior efficacy and convenience, while direct-to-consumer channels and telehealth streamline access and limit the need for in-person visits. Technology upgrades, such as less-painful IUD insertion tools, address historic barriers to uptake and broaden appeal beyond traditional demographics. Parallel investment in male contraceptive R&D signals an evolving view of shared responsibility, and retail pharmacies solidify their role as pivotal access points even as online platforms post the fastest growth. Ongoing litigation linked to IUD adverse events and cultural pushback in select regions temper, but do not derail, overall demand.
Key Report Takeaways
- By device type, condoms led with 31.36% of the United States contraceptive devices market share in 2024; hormonal IUDs are forecast to grow at an 8.43% CAGR through 2030.
- By technology, non-hormonal devices controlled 54.56% of the United States contraceptive devices market size in 2024, while hormonal devices are projected to expand at a 7.98% CAGR to 2030.
- By gender, female-focused products held 53.78% of the United States contraceptive devices market share in 2024; male contraceptives are set to post a 7.01% CAGR between 2025-2030.
- By end user, home-care and individual users commanded 66.56% of the market in 2024; clinics and community health centers are advancing at a 7.56% CAGR over the same horizon.
- By distribution channel, retail pharmacies captured 46.45% of the United States contraceptive devices market size in 2024, but online and direct-to-consumer channels will grow the fastest at a 9.12% CAGR to 2030.
U.S. Contraceptive Devices Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Medicaid reimbursement and broader employer benefits | +1.2% | North America (state Medicaid programs) | Medium term (2-4 years) |
| Accelerated LARC adoption | +1.0% | Global, strongest in North America & EU | Short term (≤ 2 years) |
| Advances in IUD insertion and delivery | +0.8% | Global, early uptake in developed markets | Medium term (2-4 years) |
| Direct-to-consumer and telehealth expansion | +0.9% | North America & EU, emerging APAC urban hubs | Short term (≤ 2 years) |
| Teen pregnancy prevention initiatives | +0.6% | Global, high-incidence regions | Long term (≥ 4 years) |
| Focus on women’s health and growing male R&D | +0.7% | Global, R&D centered in North America & EU | Long term (≥ 4 years) |
Source: Mordor Intelligence
Expansion of Medicaid Reimbursement Drives Equitable Access
The August 2024 CMS bulletin obliges states to cover family-planning services without cost-sharing, smoothing the path to LARC uptake.[1]Centers for Medicare & Medicaid Services, “Federal Policy Guidance,” medicaid.gov A JAMA Health Forum study linked separate postpartum LARC reimbursement with a 1.58 percentage-point jump in overall LARC use within 60 days after delivery, underscoring how policy shifts remove long-standing cost barriers for underserved groups.
LARCs Gain Momentum as Preferred Contraceptive Choice
Post-Dobbs demand for longer-term protection pushes more consumers toward IUDs and implants. The Bixby Center reported higher LARC requests, while Tulsa County’s Take Control Initiative distributed 2,855 IUDs and implants in 2024, reflecting heightened awareness of cost-effectiveness and reliability.
Technological Innovation Enhances User Experience
Updated CDC guidelines recognize insertion pain as a barrier and promote pain-management best practices, which, combined with device refinements such as Sebela’s flexible MIUDELLA frame, ease apprehension and improve acceptance.[3]CDC, “Selected Practice Recommendations for Contraceptive Use,” cdc.gov
Telehealth Transforms Contraceptive Access
More than half of contraceptive users now prefer remote care, according to a 2024 JAMA Network Open study, pushing investment toward digital counseling and online fulfillment. Telehealth respondents rated counseling quality comparably high, demonstrating parity with in-person visits while cutting travel and scheduling friction.[2]JAMA Network Open, “Telehealth vs In-Person Contraceptive Counseling,” jamanetwork.com
Restraints Impact Analysis
| Restraint | ( ~ ) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory uncertainty post-Dobbs | -1.1% | United States | Short term (≤ 2 years) |
| IUD-related recalls and litigation | -0.8% | Global, most acute in North America | Medium term (2-4 years) |
| Cultural and religious opposition | -0.5% | Conservative clusters in North America, MEA, APAC | Long term (≥ 4 years) |
| Limited insurance for premium devices | -0.6% | Global, dependent on system structures | Medium term (2-4 years) |
Source: Mordor Intelligence
Post-Dobbs Regulatory Uncertainty Creates Access Challenges
States with full abortion bans saw a 65% plunge in emergency contraceptive fills one year after Dobbs, along with a 25.6% fall in oral contraceptive prescriptions, stoking confusion among providers about legal parameters and hindering timely dispensing.
IUD Litigation Dampens Market Confidence
Nearly 2,937 Paragard claims are pending as of February 2025, and Mirena litigation continues, exposing manufacturers to sizable legal costs and reputational hits. Adverse-event reports exceed 53,000 for Paragard, with 22,000 labeled serious, prompting some consumers to delay or avoid IUD adoption.
Segment Analysis
By Device Type: LARCs Reshape Contraceptive Landscape
Condoms retain the largest single-device foothold at 31.36%, yet hormonal IUDs deliver the highest projected growth at 8.43% CAGR through 2030 as users shift toward longer-term solutions. The United States contraceptive devices market size for IUDs is expanding as CDC’s 2024 practice recommendations streamline placement protocols and emphasize equitable care. Copper IUD innovation accelerates with Sebela’s MIUDELLA, the first hormone-free system cleared in four decades. Niche barrier devices such as diaphragms and cervical caps serve consumers seeking on-demand, non-hormonal protection, while Evofem’s Phexxi gel re-energizes interest in hormone-free vaginal options.
Note: Segment shares of all individual segments available upon report purchase
By Technology: Non-Hormonal Options Maintain Edge
Non-hormonal methods preserved a 54.56% lead in 2024, anchored by condom ubiquity and copper-based devices. Hormonal alternatives, however, are climbing at 7.98% CAGR as advanced delivery systems lower systemic exposure and side-effects. Bayer and Daré’s ferrous gluconate ring exemplifies innovation aimed at combining convenience with lower hormonal loads. Meanwhile, research into shape-adaptive IUD frames crafted from zinc or iron reflects the market’s appetite for hormone-free designs that still guarantee robust contraception.
By Gender: Male Contraceptives Gain Momentum
Female-centered devices continue to dominate with 53.78% share, yet a sizeable 8.1 million women report using non-preferred methods, exposing unmet need. Simultaneously, male interest grows: an Andrology study estimates up to 15.5 million potential male users for new methods, and vasectomies spiked 95% after the Dobbs ruling. Innovations such as Vasalgel hydrogel filtration aim to supply durable, reversible male options, fostering diversification in the United States contraceptive devices market.
Note: Segment shares of all individual segments available upon report purchase
By End User: Clinics Drive LARC Adoption
Home and individual use accounts for 66.56% of overall sales, propelled by Opill’s over-the-counter debut at USD 19.99 per month and policy efforts to waive prescription requirements. Clinics and community health centers, however, register the fastest growth at 7.56% CAGR as initiatives like South Carolina’s Choose Well prove that on-site counseling and immediate LARC availability raise uptake.
By Distribution Channel: Digital Platforms Disrupt Traditional Retail
Retail pharmacies control 46.45% of the United States contraceptive devices market, reinforced by state policies enabling direct pharmacist prescribing. Yet online and direct-to-consumer platforms are sprinting ahead at 9.12% CAGR, reflecting consumer preference for discreet, on-demand fulfillment. Telehealth advertising spend mirrors this surge, and supply-chain networks such as VAN support efficient stock allocation to prevent shortages.
Note: Segment shares of all individual segments available upon report purchase
Geography Analysis
Regional disparities remain stark across the United States contraceptive devices market. Southern and Midwestern states record lower prescription and telehealth quality scores compared with coastal peers. Areas enforcing stringent abortion limits witness a 65% fall in emergency contraceptive orders and a 24% drop in pill prescriptions. Conversely, states legislating coverage parity—California’s Contraceptive Equity Act and New Jersey’s pharmacist-dispensing rules—expand access and spur local demand. Programs like Utah’s Family Planning Elevated and California’s policy mandates illustrate how tailored state actions can mitigate access gaps. Nationally, remote consultation options are narrowing geographic inequities by circumventing facility shortages, although broadband penetration and digital literacy still constrain uptake in rural pockets.
Competitive Landscape
The United States contraceptive devices market balances established multinationals with nimble innovators. Bayer maintains a leading hormonal IUD presence, driving an 18.4% sales jump for Mirena in Q1 2025. CooperSurgical owns the sole FDA-approved non-hormonal IUD, Paragard, after a USD 1.1 billion acquisition. Church & Dwight leverages its TROJAN brand to contribute to USD 1.51 billion in Q2 2024 net sales. Emerging players carve out specialized niches: Femasys secured CE mark for FemBloc non-surgical permanent birth control; Evofem’s Phexxi targets 23.3 million hormone-averse women; NEXT Life Sciences completed trials for Plan A male hydrogel contraception. Digital health firms add competitive pressure by controlling direct relationships with end users and using data insights to tailor product recommendations, eroding the historic dominance of brick-and-mortar channels.
U.S. Contraceptive Devices Industry Leaders
-
Cooper Surgical Inc
-
Reckitt Benckiser
-
Teva Pharmaceutical Industries Ltd
-
Church & Dwight
-
Bayer AG
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
Recent Industry Developments
- May 2025: Femasys received CE mark certification for FemBloc, the first non-surgical permanent birth-control delivery system, and plans European launch.
- February 2025: Sebela Women’s Health earned FDA approval for MIUDELLA, a flexible copper IUS slated for commercial release in 2025.
- January 2025: 3Daughters raised more than USD 2 million to advance a novel IUD.
- October 2024: The Biden administration proposed rules to widen free over-the-counter contraceptive access starting in the 2026 plan year.
U.S. Contraceptive Devices Market Report Scope
As per the scope of the report, contraceptives devices have been barriers that attempt to prevent pregnancy by physically preventing sperm from entering the uterus. Contraception is more commonly known as fertility, and birth control is described as the method used to avoid pregnancy. They include male condoms, female condoms, cervical caps, diaphragms, and contraceptive sponges with spermicide.
| By Device Type | Condoms |
| Intra-Uterine Devices (Copper IUD, Hormonal IUD) | |
| Vaginal Rings | |
| Subdermal Implants | |
| Diaphragms | |
| Cervical Caps | |
| Sponges | |
| Other Devices (Patches, Gel-Based Barriers) | |
| By Technology | Hormonal Devices |
| Non-Hormonal Devices | |
| By Gender | Male |
| Female | |
| By End User | Home-care / Individual Users |
| Hospitals | |
| Clinics and Community Health Centers | |
| Specialty and Ambulatory Surgery Centers | |
| By Distribution Channel | Retail Pharmacies and Drug Stores |
| Hospital Pharmacies | |
| Online Channels and Direct-to-Consumer Platforms |
By Device Type
| Condoms |
| Intra-Uterine Devices (Copper IUD, Hormonal IUD) |
| Vaginal Rings |
| Subdermal Implants |
| Diaphragms |
| Cervical Caps |
| Sponges |
| Other Devices (Patches, Gel-Based Barriers) |
By Technology
| Hormonal Devices |
| Non-Hormonal Devices |
By Gender
| Male |
| Female |
By End User
| Home-care / Individual Users |
| Hospitals |
| Clinics and Community Health Centers |
| Specialty and Ambulatory Surgery Centers |
By Distribution Channel
| Retail Pharmacies and Drug Stores |
| Hospital Pharmacies |
| Online Channels and Direct-to-Consumer Platforms |
Need A Different Region or Segment?
Customize Now
Key Questions Answered in the Report
1. What is the current value of the United States contraceptive devices market?
The market stands at USD 5.39 billion in 2025 and is forecast to reach USD 7.12 billion by 2030.
2. Which device type is growing the fastest?
Hormonal IUDs post the highest growth, with an expected 7.98% CAGR between 2025-2030.
3. How dominant are non-hormonal technologies?
Non-hormonal devices hold 54.56% of 2024 revenue, maintaining leadership thanks to condom ubiquity and copper-based IUDs.
4. Which distribution channel is set to expand the quickest?
Online and direct-to-consumer platforms are projected to grow at a 9.12% CAGR through 2030.
5. What impact has the Dobbs decision had on contraceptive access?
States with full abortion bans recorded a 65% decline in emergency contraceptive fills and a 25.6% drop in pill prescriptions, underscoring heightened access challenges.
6. Are male contraceptives gaining traction?
Yes. Market interest is rising, with up to 15.5 million potential users for new male methods and innovations such as Vasalgel hydrogel paving the way for long-acting reversible options.
